Anti-ryanodine receptor antibodies and FK506 in myasthenia gravis.
Anti-ryanodine receptor (RyR) antibodies were measured in sera from 33 myasthenia gravis (MG) patients using three peptides from the human RyR1 sequence, two C-terminal peptides included in the functional calcium release channel, and an N-terminal peptide implicated in ion-conduction. Antibodies were more frequently positive against the two C-terminal peptides, particularly in thymoma-associated MG. In a preliminary open trial with FK506, immunosuppressant and enhancer of RyR-related sarcoplasmic calcium release, the authors observed the sustained benefits in anti-RyR-positive MG patients.
Takamori
M
M
Neurological Center, Kanazawa-Nishi Hospital, Kanazawa, Japan. t-kiyomi@guitar.ocn.ne.jp
Motomura
M
M
Kawaguchi
N
N
Nemoto
Y
Y
Hattori
T
T
Yoshikawa
H
H
Otsuka
K
K
D000328:Adult; D000368:Aged; D001323:Autoantibodies / Q000097:blood / Q000276:immunology*; D001324:Autoantigens / Q000737:chemistry / Q000276:immunology*; D003131:Combined Modality Therapy; D004797:Enzyme-Linked Immunosorbent Assay; D000939:Epitopes / Q000276:immunology; D005260:Female; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D009157:Myasthenia Gravis / Q000097:blood / Q000188:drug therapy* / Q000209:etiology / Q000276:immunology / Q000601:surgery; D011950:Receptors, Cholinergic / Q000276:immunology; D019837:Ryanodine Receptor Calcium Release Channel / Q000737:chemistry / Q000276:immunology*; D016559:Tacrolimus / Q000627:therapeutic use*; D013934:Thymectomy; D013945:Thymoma / Q000150:complications / Q000601:surgery; D013953:Thymus Neoplasms / Q000150:complications / Q000601:surgery; D016896:Treatment Outcome
D001323:Autoantibodies; D001324:Autoantigens; D000939:Epitopes; D007166:Immunosuppressive Agents; D011950:Receptors, Cholinergic; D019837:Ryanodine Receptor Calcium Release Channel; D016559:Tacrolimus